What separates good pharma companies from great ones isn't the amount of data they have.
It's the quality of the biological decisions they make using their data. That starts with a real understanding of disease biology.
Because you can only be confident in a decision when you understand the biology behind it.
Target selection. Indication prioritization. Combination Design. Patient population prioritization. Get those right, and everything downstream improves.
It's the quality of the biological decisions they make using their data. That starts with a real understanding of disease biology.
Because you can only be confident in a decision when you understand the biology behind it.
Target selection. Indication prioritization. Combination Design. Patient population prioritization. Get those right, and everything downstream improves.